Genmab CEO strives to maintain company culture as staff count grows to 1,500

Genmab is recruiting to meet its goals for the future, which is intensifying the CEO role for Jan van de Winkel. Under his reign, the Danish biotech firm has gone from fewer than 200 people to 1,500 now.

Jan van de Winkel, CEO of Genmab | Photo: Stine Bidstrup/Ritzau Scanpix

The year that Dutch national Jan van de Winkel took over at the helm of Genmab – 2010 – the company went from having 309 employees to 189. Three years later, at the end of 2013, Genmab’s workforce counted 157.

Since then, the progress has turned around. Building out its pipeline alongside working towards an ambition of being able to handle the entire process from development to commercialization has resulted in today’s Genmab employing nearly 1,500 people with 57 different nationalities.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs